RECRUITING STUDIES

Asthma 

Dr. Curtis Veal is conducting a study for patients with moderate to severe asthma. The study evaluates the effectiveness of an investigational agent (administered orally) in the treatment of asthma.

Principal Investigator: Curtis Veal, MD
Sub-Investigator: Arvin Mokha, MD
Study Coordinator: Gary Brown, MA 
Phone: (206) 860-4761 
E-mail: research@polyclinic.com

 

Clostridium difficile infection (c-diff)

Dr. Warren Dinges is conducting a study for patients with c-diff. The study evaluates the effectiveness, safety and tolerability of an investigational agent (administered as a single infusion) in addition to standard of care (SOC) therapy in the treatment of c-diff.

Principal Investigator: Warren Dinges, MD, PhD 
Sub-Investigators: Justin Jin, MD, Michael Bolton, MD
Study Coordinator: Michelle Harder, MA
Phone: (206) 860-5432
E-mail: research@polyclinic.com

 

Diabetes (Type 2)

Dr. Michael Williams is conducting a study for patients with type 2 diabetes. The study evaluates the effectiveness of an FDA approved agent (administered once daily orally) on the incidence of cardiovascular death, myocardial infarction (heart attack) or stroke. 

Principle Investigator: Michael Williams, MD
Sub-Investigator: Ken Gross, MD
Study Coordinator: Gary Brown, MA
Phone: (206) 860-4761
E-mail: research@polyclinic.com

 

Diabetic Kidney Disease 

Dr. Lisa Nakamoto is conducting a study for patients with diabetic kidney disease. The study evaluates the safety and effectiveness of an investigational agent (administered orally) in decreasing the urinary albumin/creatinine ratio (UACR).

Principal Investigator: Lisa Nakamoto, MD
Sub-Investigator: Bruce O'Neill, MD
Study Coordinator: Kenita Davis, MA
Phone: (206) 320-6766
E-mail: research@polyclinic.com

 

Dust-Mite Induced Allergies

Dr. Arvin Mokha is conducting a study for patients with dust-mite induced allergies. The study evaluates the safety and effectiveness of an investigational agent (administered orally) in controlling dust-mite induced allergic symptoms.

Principal Investigator: Arvin Mokha, MD
Sub-Investigator: Vinod Doreswamy, MD
Study Coordinator: Gary Brown, MA 
Phone: (206) 860-4761 
E-mail: research@polyclinic.com

 

Multiple Sclerosis (Relapsing)

Dr. Braden Nago is conducting a study for patients with relapsing MS. The study evaluates the effectiveness and safety of an investigational agent (administered orally) in the treatment of relapsing MS.

Principle Investigator: Braden Nago, MD
Sub-Investigator: Alex Cooper, MD; Sameer Khan, MD; Anthony Krajcer, MD; Benduan Yang, MD
Study Coordinator: Michelle Harder, MA
Phone: (206)860-5432
E-mail: research@polyclinic.com

 

Overactive Bladder 

Dr. Emily Bradley is conducting a study for patients with overactive bladder and urinary incontinence. The study evaluates the relative safety and effectiveness of Botox in achieving 100% reduction in urinary incontinence.

Principal Investigator: Emily Bradley, MD
Sub-Investigator: Van Ginger, MD, PhD
Study Coordinator: Kenita Davis, MA 
Phone: (206) 320-6766
E-mail: research@polyclinic.com

 

Psoriatic Arthritis

Dr. Anthony Krajcer is conducting a study for patients with psoriatic arthritis. The study evaluates the effectiveness and safety of an investigational agent (administered subcutaneously) in treating psoriatic arthritis.

Principal Investigator: Anthony Krajcer, MD
Study Coordinator: Michelle Harder, MA
Phone: (206) 860-5432
E-mail: research@polyclinic.com

 

Warfarin Use

Dr. Christopher Cannon is conducting a study to determine if using warfarin-related pharmacogenetic information in calculating warfarin doses will change the incidence of warfarin-related clinical events when compared to warfarin doses calculated without pharmacogenetic data.

Principal Investigator: Christopher Cannon, MD
Sub-Investigator: Melissa Hull, PharmD
Study Coordinator: Victoria Saetern, MA 
Phone: (206) 320-6752 
E-mail: research@polyclinic.com